<SUBMISSION>
<ACCESSION-NUMBER>0000950123-09-029564
<TYPE>FWP
<PUBLIC-DOCUMENT-COUNT>2
<FILING-DATE>20090804
<DATE-OF-FILING-DATE-CHANGE>20090804
<SUBJECT-COMPANY>
<COMPANY-DATA>
<CONFORMED-NAME>MANNKIND CORP
<CIK>0000899460
<ASSIGNED-SIC>2834
<IRS-NUMBER>133607736
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>FWP
<ACT>34
<FILE-NUMBER>333-145282
<FILM-NUMBER>09983727
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>28903 NORTH AVE PAINE
<CITY>VALENCIA
<STATE>CA
<ZIP>91355
<PHONE>6617755300
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>28903 NORTH AVE PAINE
<CITY>VALENCIA
<STATE>CA
<ZIP>91355
</MAIL-ADDRESS>
</SUBJECT-COMPANY>
<FILED-BY>
<COMPANY-DATA>
<CONFORMED-NAME>MANNKIND CORP
<CIK>0000899460
<ASSIGNED-SIC>2834
<IRS-NUMBER>133607736
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>FWP
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>28903 NORTH AVE PAINE
<CITY>VALENCIA
<STATE>CA
<ZIP>91355
<PHONE>6617755300
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>28903 NORTH AVE PAINE
<CITY>VALENCIA
<STATE>CA
<ZIP>91355
</MAIL-ADDRESS>
</FILED-BY>
<DOCUMENT>
<TYPE>FWP
<SEQUENCE>1
<FILENAME>v52851fwfwp.htm
<DESCRIPTION>FWP
<TEXT>
<HTML>
<HEAD>
<TITLE>fwp</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt">Issuer Free Writing Prospectus dated August&nbsp;4, 2009<BR>
Filed Pursuant to Rule&nbsp;433<BR>
Registration No.&nbsp;333-145282<BR>
(Relating to Prospectus dated August&nbsp;15, 2007)
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><IMG src="v52851fwa5285101.gif" alt="(MANNKIND LOGO)"></DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="27%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="65%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Issuer</B>
</DIV></TD>
    <TD>&nbsp;</TD>
<TD colspan="3" align="left" valign="top">MannKind Corporation (NASDAQ: MNKD)</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
<TD colspan="3" align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD nowrap valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Common Stock Offered
by MannKind</B>
</DIV></TD>
    <TD>&nbsp;</TD>
<TD colspan="3" align="left" valign="top">7,400,000 shares of common
stock (1,000,000&nbsp;shares of which are being
purchased by our chairman, chief executive officer and principal
stockholder, Alfred&nbsp;E. Mann, from the underwriters at a price
per share equal to the greater of the public offering price or the
market value of our common stock immediately preceding the pricing of
this offering as determined by applicable Nasdaq rules; the
underwriters will not receive any underwriting discounts or
commissions on these shares).</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
<TD colspan="3" align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
<TD colspan="3" align="left" valign="top">Upon completion of this offering, we will have
111,046,376 shares of common stock outstanding based
on the actual number of shares outstanding as of June
30, 2009, which was 103,646,376, and does not
include, as of that date:</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
<TD colspan="3" align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>&#149;</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">5,476,258 shares of common stock issuable
upon the exercise of outstanding stock options with a
weighted average exercise price of $7.06 per share;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
<TD colspan="3" align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>&#149;</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3,595,482 shares of common stock issuable
upon the settlement of outstanding restricted stock
units;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
<TD colspan="3" align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>&#149;</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">5,117,523 shares of common stock issuable
upon the conversion of our outstanding 3.75% senior
convertible notes due 2013 at a conversion price of
approximately $22.47 per share;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
<TD colspan="3" align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>&#149;</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2,882,873 shares of common stock reserved for
issuance upon the exercise of outstanding warrants
with a weighted average exercise price of $12.23 per
share; and</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
<TD colspan="3" align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>&#149;</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9,487,966 shares of common stock available
for future grant under our 2004 equity incentive
plan, 2004 non-employee directors&#146; stock option plan
and 2004 employee stock purchase plan.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
<TD colspan="3" align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
<TD colspan="3" align="left" valign="top">In addition, we have
granted the underwriters an option to purchase up to an additional
960,000&nbsp;shares of common stock. Except as otherwise indicated,
all information in this issuer free writing prospectus assumes
exercise by the underwriters of this option.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
<TD colspan="3" align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Use of Proceeds</B>
</DIV></TD>
    <TD>&nbsp;</TD>
<TD colspan="3" align="left" valign="top">We intend to use the net proceeds from this offering
for general corporate purposes, including clinical
trial expenses, research and development expenses,
general and administrative expenses, manufacturing
expenses, and potential acquisitions of companies and
technologies that complement our business.</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="27%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="65%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Risk Factors</B>
</DIV></TD>
    <TD>&nbsp;</TD>
<TD colspan="3" align="left" valign="top"><I>Before you make a decision to invest in our common
stock, you should consider carefully the risks
described below, and in the section entitled &#147;Risk
Factors&#148; contained in our quarterly report on Form
10-Q for the fiscal quarter June&nbsp;30, 2009, as filed
with the SEC on August&nbsp;3, 2009, together with other
information in the prospectus to which this issuer
free writing prospectus relates, and the information
incorporated by reference therein.</I></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
<TD colspan="3" align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
<TD colspan="3" align="left" valign="top"><B>Risks Related to Our Offering</B></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
<TD colspan="3" align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
<TD colspan="3" align="left" valign="top"><B><I>Management will have broad discretion as to the use
of the proceeds from this offering, and we may not
use the proceeds effectively.</I></B></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
<TD colspan="3" align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
<TD colspan="3" align="left" valign="top">We intend to use the net proceeds from this offering
for general corporate purposes, including clinical
trial expenses, research and development expenses,
general and administrative expenses, manufacturing
expenses, and potential acquisitions of companies and
technologies that complement our business.
Accordingly, our management will have broad
discretion as to the application of the net proceeds
from this offering, and could spend the proceeds in
ways that do not necessarily improve our operating
results or enhance the value of our common stock.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
<TD colspan="3" align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Our Business</B>
</DIV></TD>
    <TD>&nbsp;</TD>
<TD colspan="3" align="left" valign="top">MannKind Corporation is a biopharmaceutical company
focused on the discovery, development and
commercialization of therapeutic products for
diseases such as diabetes and cancer. Our lead
product candidate is an ultra rapid-acting insulin
known as AFRESA, which is also the trade name for the
product that we have proposed to the United States
Food and Drug Administration, or FDA. In March&nbsp;2009,
we submitted a new drug application, or NDA, to the
FDA requesting approval of AFRESA for the treatment
of adults with type 1 or type 2 diabetes for the
control of hyperglycemia. The FDA accepted our NDA
for filing in May&nbsp;2009. We believe that the
performance characteristics, unique kinetics,
convenience and ease of use of AFRESA have the
potential to change the way diabetes is treated.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
<TD colspan="3" align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
<TD colspan="3" align="left" valign="top">We believe that a distinguishing characteristic of
AFRESA is that it produces a profile of insulin
levels in the bloodstream that approximates the
insulin profile normally seen in healthy individuals
immediately following the beginning of a meal, but
which is absent in patients with diabetes.
Specifically, AFRESA is rapidly absorbed into the
bloodstream following inhalation, reaching peak
levels within 12 to 14 minutes. As a result of this
rapid absorption, most of the glucose-lowering
activity of AFRESA occurs within the first three
hours of administration &#151; which is generally when
glucose becomes available from a meal &#151; instead of
the much longer duration of action observed when
insulin is injected subcutaneously. We believe that
the relatively short duration of action of AFRESA
reduces the need for patients to snack between meals
in order to manage ongoing blood glucose excursions.
In our clinical trials, we have observed that
patients using AFRESA have achieved significant
reductions in post-meal glucose excursions and
significant improvements in overall glucose control,
as measured by decreases in glycosylated hemoglobin,
or A1C, levels, without the weight gain typically
associated with insulin therapy.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
<TD colspan="3" align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
<TD colspan="3" align="left" valign="top">We have conducted an extensive clinical program,
involving more than 40 different studies of AFRESA.
Approximately 5,300 subjects participated in our
clinical studies, of which more than 2,900 subjects
were administered AFRESA. These studies were
conducted in healthy volunteers, patients with type 1
and type 2 diabetes as well as diabetic patients with
renal dysfunction, liver dysfunction, chronic
obstructive pulmonary disease, asthma and upper
respiratory tract infections. In addition, we have
completed construction and achieved operational
readiness of our production facility in Danbury,
Connecticut. We believe that our facility will
satisfy the initial commercial demand for AFRESA. The
facility also includes expansion space that will
allow production capacity to be increased based on
anticipated needs during the initial years of
commercialization. We are preparing for pre-approval
inspection of the facility by the FDA. We will only
be able to market AFRESA in the United States once,
and if, the FDA approves our application.</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="27%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="65%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
<TD colspan="3" align="left" valign="top">AFRESA utilizes our proprietary Technosphere
formulation technology, which is based on a class of
organic molecules that are designed to self-assemble
into small particles onto which drug molecules can be
loaded. Technosphere technology is not limited to
insulin delivery. We believe it represents a
versatile drug delivery platform that may allow
pulmonary administration of certain drugs that
currently require administration by injection. Beyond
convenience, we believe the key advantage of drugs
inhaled as Technosphere formulations is that they
have been shown to be absorbed very rapidly into the
arterial circulation.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
<TD colspan="3" align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
<TD colspan="3" align="left" valign="top">We are also developing therapies for the treatment of
different types of cancer, which do not utilize our
Technosphere platform. We are currently completing
two clinical trials of our therapeutic cancer
vaccines. We expect to announce the results of these
trials by the end of 2009.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Sole
Book-Running Manager</B>
</DIV></TD>
    <TD>&nbsp;</TD>
<TD colspan="3" align="left" valign="top">Jefferies &#038; Company,
Inc.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
<TD colspan="3" align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Co-Manager</B>
</DIV></TD>
    <TD>&nbsp;</TD>
<TD colspan="3" align="left" valign="top">Rodman&nbsp;&#038; Renshaw, LLC</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: 100%; border-top: 1px solid #000000">&nbsp;</DIV></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">We have filed a registration statement and a prospectus with the Securities and Exchange
Commission, or SEC, for the offering to which this communication relates. This registration statement and prospectus included therein can be
accessed through the following link:
<U>http://www.sec.gov/Archives/edgar/data/899460/000095014807000184/v32369sv3.htm</U>.
Before you invest, you
should read the prospectus in that registration statement and other documents we have filed with
the SEC for more complete information about us and this offering. You may get these documents for
free by visiting EDGAR on the SEC Web site at <I>www.sec.gov</I>. Alternatively, we or the underwriters
for this offering will arrange to send you the prospectus if you request it from Jefferies &#038;
Company, Inc., Attention: Syndicate Prospectus Department, 520 Madison Avenue, New York, NY, 10022
or at (888)&nbsp;449-2342.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>v52851fwa5285101.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 v52851fwa5285101.gif
M1TE&.#EA*`!3`-4N`//U^<[6Z)NMT+3"W.?K]+_&W=KA[L',XJ2QT8"4P8F;
MQ41DIU!OK8^BRH*8Q&F#N:VXU:BWUEUYL[:_V9NIS7J/OWN2P':,O7^5PHN?
MR'&(NW2,O9*BR7:.OFN$N'>.OV^'NX29Q6V%N7Z3P4!AI7**O&>`MXV@R&1^
MM8B<QDEHJ8.7P\G.XC=:H?___P``````````````````````````````````
M`````````````````````````````````"'Y!`$``"X`+``````H`%,```;_
M0)=P.!PXB,BD<JD</)A0%V$0)0X6@"HS<JP&2`<M]"'),@D:BQAJ:)69($5@
M#>VXEP+(B`X]M%I=1`8)!0U5!@<1`69+"W]A1!8L"'-,!QL<$!,4%0V,2'8M
M6$44+`F?2`X*+*RM$!^H0@)_+0)#&ZP)6QRMO2P%($VTHP>\IDL$%;Z^"%1(
M`;0M5"FMNDH"$\N^&TG0M!T`%]5+(=J^"@9(`]$+!PBM"@1*XN:ME$BST0*]
M]TD)]?8J#0E%JURK`K:2*`,X2:`0!M%:G/`50HDDA@GD#6D3\5^O"[$&O`.H
MADB#B"T\NG)&!`"N>@H@#8$8<<2RDL]$F(.001U*_XG+XC6I4.!<3R0/4$IH
ML*S`T20$,E10P"&!!9E%?CH8`&'9!8W(TBD!0#/B@7#+)@3B<_)G%@S:,O)Q
MP1%EEP#&>A7`,%?"SQ9@+YYS6"7"W[4!5BW[L`:`(Y2CB)0HRBQA%0=_+0\A
MH++7"K!,O*%DL"0#9;TEJOC]B94(`7J^*$2`8OCG$R;8M&F()<3QSP6@DP#0
MH&WO$H(1->,9&;NU"]$126MYN6QWR[(1"5O*JY?OD+9VZ5@XW4NVD+H1(XL9
M9$Z#O-4H6:YID"WH@7PH;_,!8"(M!O3L!+?&`*7T8@(`\"4W5R2G<7#?7Q(L
M*`@]>T$7D5@2RM*5>]CID_\A$A_(!EYTO"UHP`,6>O@A$F3]=8%U*W[WEPH%
M&!?C<W^U,)(<,?KVDTZM;%#B&IC]1`)Y$"C'1XJT%-A+`ACNUR$M*!2'$ULY
M*K8,`K,MF>,!&72EVY!+3/E'!T*`0%XK$SRE!7[IF8&&.3QJ`6`T6!V@I2\>
MB)%@-&@BT8"8E54!9S0,\/;!FJQ4(*!KCZ&DW7FP=3?&7X9LX60O=2:QSD^)
M1H%!?7R.968+D[+H`:,(*'DH+9D>LI`O%:`2*:)DJL,=*Q-H]BE*SD41YC*U
M#O'G'_HUYL$R$'1)P%^/'M(9*XRY\&LT:[%%:BY9O`I8ABXQ,T=2$64[ETB]
M3#!,&[G11$L'=:S8PBZR-Z++RCV'RO?AK$+Y$4VN:V302I\N^-A"LBMR-0E+
D^"F980"E$-P;3<%*.,@%4=+E2*H+!B""ON<QP/%<6Q$1!``[
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
